Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Merck

    Tag: Merck

    You Searched For "Merck"
    Merck KEYTRUDA gets USFDA priority review for its Second Application

    Merck KEYTRUDA gets USFDA priority review for its Second Application

    Medical Dialogues Bureau9 April 2020 3:30 AM GMT
    Kenilworth: Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted and...
    Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer

    Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer

    Medical Dialogues Bureau28 March 2020 6:15 AM GMT
    TEPMETKO is the first regulatory approval globally for an oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene...
    Merck Announces positive results for Gefapixant  Phase 3 Trial to treat Chronic Cough

    Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough

    Medical Dialogues Bureau21 March 2020 4:45 AM GMT
    Kenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...
    Merck, AMCM collaborates for 3D Printing of Tablets

    Merck, AMCM collaborates for 3D Printing of Tablets

    Medical Dialogues Bureau1 March 2020 5:00 AM GMT
    3D printing allows for API (active pharmaceutical development) formulation to be scalable while avoiding costly reformulations throughout the entire...
    Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations

    Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations

    Medical Dialogues Bureau24 Dec 2019 3:30 AM GMT
    The vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that...
    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Medical Dialogues Bureau3 Nov 2019 3:30 AM GMT
    Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Farhat Nasim31 Oct 2019 9:57 AM GMT
    In 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
    Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus

    Medical Dialogues Bureau23 Sep 2019 8:46 AM GMT
    Novo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with...
    Sanofi revival depends on outsider with nose for big drugs: Report

    Sanofi revival depends on outsider with nose for big drugs: Report

    Medical Dialogues Bureau3 Sep 2019 3:28 AM GMT
    Defining Sanofi's ambitions in the cutting-edge field of gene therapies and figuring out whether to hold on to consumer health brands are among other...
    GSK Belantamab Mafodotin shows to help blood cancer patients

    GSK Belantamab Mafodotin shows to help blood cancer patients

    Medical Dialogues Bureau26 Aug 2019 3:45 AM GMT
    Two doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the...
    Canada enacts drug price crackdown, in blow to pharmaceutical industry

    Canada enacts drug price crackdown, in blow to pharmaceutical industry

    Medical Dialogues Bureau11 Aug 2019 3:30 AM GMT
    The changes are the biggest reform to Canada's drug price regime since 1987 and could eventually cut the earnings of drugmakers in the United States,...
    Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

    Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

    Medical Dialogues Bureau28 July 2019 3:47 AM GMT
    Sales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    X